GO
Loading...

Enter multiple symbols separated by commas

Johnson & Johnson Profit Rises on Higher Drug Sales

Johnson & Johnson said its quarterly profit rose, helped by growing sales of its drugs and consumer products, although stent sales fell sharply.

The diversified health-care company earned $2.17 billion, or 74 cents a share in the fourth quarter, compared with $2.1 billion, or 70 cents, a year earlier.

Excluding items, J&J earned 81 cents a share. Analysts on average expected a profit of 79 cents per share, according to Thomson Financial.

The results included $217 million in charges related to the company's $16.6 billion acquisition in December of Pfizer's consumer health products, including such brands as Listerine mouthwash and the Sudafed allergy drug. Sales of the former Pfizer products were not included in J&J's fourth-quarter results.

Sales rose 8.5 percent to $13.7 billion.

Consumer product revenues -- including the New Brunswick, N.J.-based company's Aveeno skin products and sun care products acquired from another acquisition, jumped 11.2% in the quarter to $2.57 billion.

Global pharmaceutical sales rose 8.5% to $5.95 billion, helped by strong demand for schizophrenia drug Risperdal and epilepsy treatment Topamax.

Global Risperdal sales rose 18% to $1.06 billion, despite strong competition with Bristol-Myers Squibb's newer Abilify. Sales of Topamax jumped 28% to $529 million.

Sales of arthritis drug Remicade grew 13% to $780 million, while those of attention deficit disorder treatment Concerta rose 24% to $257 million.

But combined sales of anemia drugs Procrit and Eprex slipped 1% to $788 million, hurt by longer-acting rival Aranesp sold by Amgen.

Sales of medical devices and diagnostics rose 7.2% to $5.17 billion, although global sales of the company's drug-coated Cypher stent fell 15% to $580 million.

U.S. sales of Cypher, used to prop open cornary arteries that have been cleared of plaque, fell 18% to $280 million, with sales hurt by overall softness in demand for the devices.

Sales of drug-coated stents have been hurt by reports showing they can cause blood clots.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • Hero miles for military members: Real estate magnate's plea

    Chairman of the Fisher House Foundation, Ken Fisher, discusses the Hero Miles program with CNBC's Dina Gusovsky. During Military Appreciation Month, Fisher is asking every traveler to donate 1,000 of their miles to replenish the Hero Miles programs that is in danger of running out.

  • Cramer shuts down this market's haters

    "Mad Money" host Jim Cramer on why this market can't stop, won't stop.

  • From the battlefield to the boardroom

    Your Grateful Nation is dedicated to helping Special Forces veterans enter the corporate world and Knot Standard provides complimentary suits to vets. Mad Money's Jim Cramer spoke with Rob Clapper, Your Grateful executive director; John Ballay, Knot Standard co-founder and president; Tej Gill, retired U.S. Navy Seal; and Darren McB, active duty U.S. Navy Seal.